Skip to content

Evaluating the Association of Glycemic and Heart-Rate Variability with Atrial fibrillation Recurrence and Adverse Cardiovascular Events

Evaluating the Association of Glycemic and Heart-Rate Variability with Atrial fibrillation Recurrence and Adverse Cardiovascular Events

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0010971
Enrollment
100
Registered
2025-09-02
Start date
2025-09-29
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Korea University Anam Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults aged 20 years or older, male or female, scheduled to undergo catheter ablation for atrial fibrillation 2. Patients with prediabetes or type 2 diabetes with glycated hemoglobin (HbA1c) = 6% 3. Able to wear a continuous glucose monitoring (CGM) device and a wearable ECG patch for =15 days, and capable of using a smartphone application

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 diabetes or a history of pancreatic resection 2. Patients unable to attach patches due to severe dermatologic disease or allergy 3. Patients diagnosed with solid or hematologic malignancy and receiving active treatment within the past 5 years 4. Patients requiring continuous systemic corticosteroid use at screening 5. Patients requiring long-term (=6 months) immunosuppressant therapy 6. Patients with renal impairment (eGFR 3× upper limit or liver cirrhosis) 7. Patients with a history of severe psychiatric disorder or currently receiving psychiatric medication 8. Patients deemed unsuitable for study participation at the investigator’s discretion

Design outcomes

Primary

MeasureTime frame
Atrial fibrillation recurrence within 12 months

Secondary

MeasureTime frame
Correlation between pre-procedural glycemic variability (GV) indices and heart rate variability (HRV) indices;Predictive value of differences in glycemic variability and heart rate variability before and after the procedure for atrial fibrillation recurrence;Evaluation of cardiovascular events according to changes in glycemic variability and heart rate variability before and after the procedure;Evaluation of device-related adverse events, including skin irritation, rash, and infection at the site of continuous glucose monitoring (CGM) sensor or wearable ECG patch application

Countries

Korea, Republic of

Contacts

Public ContactJung A Kim

Korea University Anam Hospital

frances.junga@gmail.com+82-2-920-5890

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026